Abingdon Health PLC
LSE:ABDX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.75
12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Abingdon Health PLC
Abingdon Health PLC
Revenue
Abingdon Health PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abingdon Health PLC
LSE:ABDX
|
Revenue
£4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
ConvaTec Group PLC
LSE:CTEC
|
Revenue
$2.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Tristel PLC
LSE:TSTL
|
Revenue
£39.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
|
Inspecs Group PLC
LSE:SPEC
|
Revenue
£203.3m
|
CAGR 3-Years
62%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Advanced Medical Solutions Group PLC
LSE:AMS
|
Revenue
£131.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Cambridge Nutritional Sciences PLC
LSE:CNSL
|
Revenue
£9.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abingdon Health PLC
Glance View
Abingdon Health Plc develops, manufactures and commercializes immunoassay tests and reader systems. The company is headquartered in York, North Yorkshire and currently employs 151 full-time employees. The company went IPO on 2020-12-15. The firm operates through three segments: Contract Development, Contract Manufacturing and Product Sales. The Contract Development segment comprises development work for third parties and is recognized over time based on a proportion of completion. The Contract Manufacturing segment comprises contract development and manufacturing activities. The Product Sales segment comprises the sale of ABC-19, pocket diagnostic products, progressive rod cone degeneration (PCRD) tests and antibodies for research use. Its products also include Seralite, which includes Free Light Chain (FLC) Serum. The Company’s geographical market include the United Kingdom, the United States/Canada, rest of world (ROW).
See Also
What is Abingdon Health PLC's Revenue?
Revenue
4m
GBP
Based on the financial report for Jun 30, 2023, Abingdon Health PLC's Revenue amounts to 4m GBP.
What is Abingdon Health PLC's Revenue growth rate?
Revenue CAGR 5Y
12%
Over the last year, the Revenue growth was 43%. The average annual Revenue growth rates for Abingdon Health PLC have been -8% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
